Our leading
AI-driven drug discovery pipeline

Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets.

We focus on indications with high unmet need, including oncology and rare disease.

Target
Disease Indication
Late Discovery
Preclinical
Phase 1/2
Pivotal/Phase 3
Read More
Oncology
REC-617
CDK7
Advanced Solid Tumors
Status:
Phase 1/2
Designation
Population:

~185,0001

REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.

Read More

Learn more on clinicaltrials.gov.

1. Annual incidence for patient types eligible for inclusion in Phase 1/2 ELUCIDATE trial. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
REC-1245
RBM39
Biomarker-Enriched Solid Tumors and Lymphoma
Status:
Phase 1
Designation
Population:

REC-1245 targets RBM39, a novel CDK12-adjacent target identified by the Recursion OS. We believe we can modulate this target to produce a therapeutic effect in biomarker-enriched solid tumors and lymphoma.

Read More

REC-3565
MALT1
B-Cell Malignancies
Status:
Phase 1
Designation
Population:

~41,0002

REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.

Learn more on euclinicaltrials.eu.

2. Annual incidence of relapsed/refractory chronic lymphocytic leukemia and B-cell lymphomas. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
REC-4539*
LSD1
Small-Cell Lung Cancer
Status:
Strategic pause
Designation
Population:

~45,0003

Note: due to competitive landscape, REC-4539 is on strategic pause*.

REC-4539 is the first LSD1 inhibitor designed to be both CNS-penetrant and reversible, and is being developed for multiple hematology and solid tumor indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.

3. Annual incidence of extensive stage SCLC. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
REC-7735
PI3Kα H1047R
Breast Cancer
Status:
Preclinical
Designation
Population:

~11,000

REC-7735 is a PI3Kα H1047R mutant selective inhibitor being developed for the treatment of HER2- HR+ Breast cancer where the PI3Kα-H1047R mutation is present, representing 14% of such cases in the US and EU5 and addressing ~11,000 patients. This highly selective inhibitor targets the most frequent PIK3CA mutation and a key driver of cancer. The molecule was designed to maximize the therapeutic window and to avoid dose-limiting hyperglycemia or other off-target AEs associated with wild-type PI3Kα inhibition. Preclinical models have shown tumor regression when used as a monotherapy treatment and when combined with standard of care.

Rare Diseases
REC-4881
MEK Inhibitor
Familial Adenomatous Polyposis
Status:
Phase 2
Designation
Fast Track; US and EU Orphan Drug
Population:

~50K4

REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. There are currently no FDA-approved therapies for the treatment of FAP, a rare tumor predisposition syndrome affecting approximately 50,000 people in the US, France, Germany, Italy, Spain and the UK.

Read More

Learn more on clinicaltrials.gov.

4. Prevalence for adult and pediatric population. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
REC-102
ENPP1
Hypophosphatasia
Status:
Candidate profiling
Designation
Population:

>7,8005

REC-102 is an orally available, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.

5. Estimated prevalence ranges of mild-moderate HPP based on ALPL gene variants of a European population.
Partnerships

We partner with leading data & capability partners, and therapeutic partners to discover and develop new medicines across oncology, rare disease, neuroscience, immunology and inflammation. More on our partnerships →

Year Initiated
Highlights
Neuroscience & Immunology
First neuroscience phenomap in human cell context. One optioned GI oncology program continues to advance. Potential for up to 40 programs​
Oncology & Immunology
Milestones achieved across four distinct BIC and FIC discovery programs in 18 months; potential for several program milestones upcoming​
Oncology
Advancing multiple programs with previously “undruggable” targets to lead series milestones​
Oncology & Immunology
Multi-year collaboration to identify and advance first-in-class and best-in-class programs​

Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets.

We focus on indications with high unmet need, including oncology and rare disease.

Oncology
REC-617
Advanced Solid Tumors
Phase 1/2
|
|
Target / MOA:

CDK7

Status:

Phase 1/2

Designation
Population:

~185,0001

REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.

Read More

Learn more on clinicaltrials.gov.

1. Annual incidence for patient types eligible for inclusion in Phase 1/2 ELUCIDATE trial. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-1245
Biomarker-Enriched Solid Tumors and Lymphoma
Phase 1/2
|
|
Target / MOA:

RBM39

Status:

Phase 1

Designation
Population:

REC-1245 targets RBM39, a novel CDK12-adjacent target identified by the Recursion OS. We believe we can modulate this target to produce a therapeutic effect in biomarker-enriched solid tumors and lymphoma.

Read More

Video
REC-3565
B-Cell Malignancies
Phase 1/2
|
|
Target / MOA:

MALT1

Status:

Phase 1

Designation
Population:

~41,0002

REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.

Learn more on euclinicaltrials.eu.

2. Annual incidence of relapsed/refractory chronic lymphocytic leukemia and B-cell lymphomas. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-4539*
Small-Cell Lung Cancer
Preclinical
|
|
Target / MOA:

LSD1

Status:

Strategic pause

Designation
Population:

~45,0003

Note: due to competitive landscape, REC-4539 is on strategic pause*.

REC-4539 is the first LSD1 inhibitor designed to be both CNS-penetrant and reversible, and is being developed for multiple hematology and solid tumor indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.

3. Annual incidence of extensive stage SCLC. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-7735
Breast Cancer
Late Discovery
|
|
Target / MOA:

PI3Kα H1047R

Status:

Preclinical

Designation
Population:

~11,000

REC-7735 is a PI3Kα H1047R mutant selective inhibitor being developed for the treatment of HER2- HR+ Breast cancer where the PI3Kα-H1047R mutation is present, representing 14% of such cases in the US and EU5 and addressing ~11,000 patients. This highly selective inhibitor targets the most frequent PIK3CA mutation and a key driver of cancer. The molecule was designed to maximize the therapeutic window and to avoid dose-limiting hyperglycemia or other off-target AEs associated with wild-type PI3Kα inhibition. Preclinical models have shown tumor regression when used as a monotherapy treatment and when combined with standard of care.

Rare Diseases
REC-4881
Familial Adenomatous Polyposis
Phase 1/2
|
|
Target / MOA:

MEK Inhibitor

Status:

Phase 2

Designation
Fast Track; US and EU Orphan Drug
Population:

~50K4

REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. There are currently no FDA-approved therapies for the treatment of FAP, a rare tumor predisposition syndrome affecting approximately 50,000 people in the US, France, Germany, Italy, Spain and the UK.

Read More

Learn more on clinicaltrials.gov.

4. Prevalence for adult and pediatric population. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-102
Hypophosphatasia
Preclinical
|
|
Target / MOA:

ENPP1

Status:

Candidate profiling

Designation
Population:

>7,8005

REC-102 is an orally available, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.

5. Estimated prevalence ranges of mild-moderate HPP based on ALPL gene variants of a European population.
View Poster
Partnerships

We partner with leading data & capability partners, and therapeutic partners to discover and develop new medicines across oncology, rare disease, neuroscience, and immunology & inflammation. More on our partnerships →

Oncology
25 data packages delivered to date
Neuroscience & Immunology
1st phenomap optioned in 2024 ; 5 phenomaps delivered to date
Oncology & Immunology
4 program milestones achieved to date
Oncology & Immunology
Multi-year collaboration to identify first-in-class and best-in-class targets across oncology and immunology
Expanded Access PolicyClinical Trial Transparency

FROM BIOTECH TO TECHBIO

By leveraging technology at every step of the process, we can accelerate the development of high potential drug candidates once we have validated their potential.

Our approach
© 2025 Recursion. All rights reserved.